title: MRI to assess chemoprevention in transgenic adenocarcinoma of mouse prostate (TRAMP).
abstract: BACKGROUND
  The current method to determine the efficacy of chemoprevention in TRAMP mouse model of carcinoma of prostate (CaP) is by extracting and weighing the prostate at different time points or by immunohistochemistry analysis. Non-invasive determination of volumes of prostate glands and seminal vesicles before, during and after treatment would be valuable in investigating the efficacy of newer chemopreventive agents in CaP. The purpose of this study was to determine whether in vivo magnetic resonance imaging (MRI) using a 3 tesla clinical MRI system can be used to follow the effect of chemoprevention in TRAMP model of mouse CaP.
  
  
  METHODS
  Mice were randomized into control and treated groups. The animals in treated group received 10 µmol/kg of CDDO, 5 days a week for 20 weeks. Animals underwent in vivo MRI of prostate gland and seminal vesicles by a clinical 3 Tesla MRI system just before (at 5 weeks), during and at the end of treatment, at 25 weeks. T1-weighted and fat saturation (FATSAT) multiecho fast spin echo T2-weighted images (T2WI) were acquired. Volume of the prostate glands and seminal vesicles was determined from MR images. T2 signal intensity changes in the seminal vesicles were determined by subtracting higher echo time (TE) from lower TE T2WI. Following treatments all animals were sacrificed, prostate and seminal vesicles collected, and the tissues prepared for histological staining. All data were expressed as mean ± 1 standard deviation. Two-way or multivariate analysis of variance followed by post-hoc test was applied to determine the significant differences. A p-value of <0.05 was considered significant.
  
  
  RESULTS
  Histological analysis indicated tumor in 100% of control mice, whereas 10% of the treated mice showed tumor in prostate gland. Both MRI and measured prostate weights showed higher volume/weight in control mouse group. MRI showed significantly higher volume of seminal vesicles in control animals and T2 signal intensity changes in seminal vesicles of control mice indicating higher number of tumor foci, which was also proven by histology.
  
  
  CONCLUSIONS
  In vivo MRI is helpful in determining the efficacy of chemoprevention of prostate cancer in TRAMP mice.
authors.affiliation: Department of Radiology, Henry Ford Hospital, 1 Ford Place, 2F, Detroit, MI 48202, USA. saali@rad.hfh.edu
authors.forename: Ali S
authors.initials: AS
authors.lastname: Arbab
authors.forename: Adarsh
authors.initials: A
authors.lastname: Shankar
authors.forename: Nadimpalli R S
authors.initials: NR
authors.lastname: Varma
authors.forename: Dorrah
authors.initials: D
authors.lastname: Deeb
authors.forename: Xiaohua
authors.initials: X
authors.lastname: Gao
authors.forename: A S M
authors.initials: AS
authors.lastname: Iskander
authors.forename: Branislava
authors.initials: B
authors.lastname: Janic
authors.forename: Meser M
authors.initials: MM
authors.lastname: Ali
authors.forename: Subhash C
authors.initials: SC
authors.lastname: Gautam
mesh_terms: D000818:Animals; D018890:Chemoprevention; D018450:Disease Progression; D008279:Magnetic Resonance Imaging; D008297:Male; D051379:Mice; D008822:Mice, Transgenic; D009828:Oleanolic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011467:Prostate / Q000473:pathology; D011471:Prostatic Neoplasms / Q000473:pathology / Q000517:prevention & control*; D012669:Seminal Vesicles / Q000473:pathology
chemical_list: C116817:2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid; D009828:Oleanolic Acid